Amgen's SWOT analysis: obesity program drives stock outlook By Investing.com

Published on 15 Dec 2024 on Investing.com

According to InvestingPro data, the company maintains a strong financial health score and has...

Read the rest of the article

Start tracking your investments with Statfolio

The pharmaceutical behemoth said its experimental weight-loss treatment helped patients lower the...

Invezz 20 Dec 2024

CT-388, a dual GLP-1/GIP receptor agonist, is being evaluated for the treatment of obesity in pat...

Zacks · via Yahoo Finance 19 Dec 2024

We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this artic...

Insider Monkey · via Yahoo Finance 19 Dec 2024

Amgen's SWOT analysis: stock poised for growth amid obesity market potential

Investing.com 18 Dec 2024

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In...

Insider Monkey · via Yahoo Finance 17 Dec 2024

According to InvestingPro data, the company maintains a strong financial health score and has...

Investing.com 15 Dec 2024

Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures and delivers human therapeutics...

Benzinga · via Yahoo Finance 14 Dec 2024

We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article...

Insider Monkey · via Yahoo Finance 12 Dec 2024

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is...

Zacks · via Yahoo Finance 10 Dec 2024

The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since...

Los Angeles Business Journal 9 Dec 2024